Copper-Catalyzed Electrophilic Amination of Heteroarenes and Arenes by CH Zincation
作者:Stacey L. McDonald、Charles E. Hendrick、Qiu Wang
DOI:10.1002/anie.201311029
日期:2014.4.25
Direct amination of heteroarenes and arenes has been achieved in a one‐pot CH zincation/copper‐catalyzed electrophilic amination procedure. This amination method provides an efficient and rapid approach to access a diverse range of heteroaromatic and aromatic amines including those previously inaccessible using CH amination methods. The mild reaction conditions and good functional‐group compatibility
杂芳烃和芳烃的直接胺化已经在一锅C - H锌化/铜催化的亲电胺化过程中实现。这种胺化方法提供了一种高效、快速的方法来获得各种杂芳胺和芳香胺,包括以前使用 C - H 胺化方法无法获得的胺。温和的反应条件和良好的官能团相容性证明了其在合成重要且复杂的胺类方面的巨大潜力。
Metal-Free Synthesis of Heteroaryl Amines or Their Hydrochlorides via an External-Base-Free and Solvent-Free C–N Coupling Protocol
Herein, a metal-free and solvent-free protocol was developed for the C–N coupling of heteroaryl halides and amines, which afforded numerous heteroaryl amines or their hydrochlorides without any external base. Further investigations elucidated that the basicity of amines and specific interactions derived from the X-ray crystallography analysis of 3j′·HCl played pivotal roles in the reactions. Moreover
在此,开发了一种无金属和无溶剂的方案,用于杂芳基卤化物和胺的 C-N 偶联,在没有任何外部碱的情况下提供了许多杂芳基胺或其盐酸盐。进一步的研究表明,胺的碱性和源自3j'·HCl的 X 射线晶体学分析的特定相互作用在反应中起关键作用。此外,该协议可扩展到克级并适用于药物分子,这证明了其进一步应用的实用价值。
BENZIMIDAZOLYL COMPOUNDS
申请人:Efremov Ivan
公开号:US20080280933A1
公开(公告)日:2008-11-13
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, R
A
is a hydrogen atom and the like, X is the formula (b3) wherein R
B
is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R
1
is a hydrogen atom and the like, and R
C
and R
D
are the same or different and each is a hydrogen atom and the like, and the like, which has a PPARγ agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.